Q2 2022 · 13F-HR
CHI Advisors LLCholdings as filed
Filed 2022-08-12 · accession 0001085146-22-003022
$261,836
Reported value
28
Positions
2022-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74349U108 | — | PROMETHEUS BIOSCIENCES INC | $47,200 | 18.0% | 1,671,976 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $39,070 | 14.9% | 3,047,609 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $37,028 | 14.1% | 2,646,781 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $24,886 | 9.50% | 3,106,807 | Common | SOLE |
| H9060V101 | — | VECTIVBIO HLDG AG | $20,424 | 7.80% | 3,782,199 | Common | SOLE |
| 49372L100 | — | KEZAR LIFE SCIENCES INC | $15,223 | 5.81% | 1,840,793 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $10,820 | 4.13% | 819,672 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $9,701 | 3.70% | 2,033,802 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $7,499 | 2.86% | 2,829,712 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $4,833 | 1.85% | 1,090,937 | Common | SOLE |
| 74019P108 | — | PRECISION BIOSCIENCES INC | $4,806 | 1.84% | 3,003,751 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $4,411 | 1.68% | 358,013 | Common | SOLE |
| 35655L107 | — | FREELINE THERAPEUTICS HLDGS | $4,230 | 1.62% | 4,862,319 | Common | SOLE |
| 68217N105 | — | OMEGA THERAPEUTICS INC | $4,012 | 1.53% | 1,055,882 | Common | SOLE |
| 00973J101 | — | AKOUOS INC | $3,921 | 1.50% | 836,120 | Common | SOLE |
| 3621LQ109 | GTHXEUR | G1 THERAPEUTICS INC | $3,790 | 1.45% | 767,235 | Common | SOLE |
| 68570P101 | — | ORCHARD THERAPEUTICS PLC | $3,101 | 1.18% | 5,307,751 | Common | SOLE |
| 68236R103 | — | ONCORUS INC | $2,983 | 1.14% | 2,367,436 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $2,970 | 1.13% | 1,515,148 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $2,858 | 1.09% | 103,429 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $2,192 | 0.84% | 2,214,184 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $1,991 | 0.76% | 163,496 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $1,859 | 0.71% | 864,822 | Common | SOLE |
| 28249U105 | CLDNEUR | EIGER BIOPHARMACEUTICALS INC | $1,197 | 0.46% | 190,000 | Common | SOLE |
| 717224109 | — | PHASEBIO PHARMACEUTICALS INC | $450 | 0.17% | 750,000 | Common | SOLE |
| 78464A870 | XBI | SPDR SER TR | $372 | 0.14% | 157,000 | PUT | SOLE |
| 49372L100 | — | KEZAR LIFE SCIENCES INC | $5 | 0.00% | 100,000 | CALL | SOLE |
| 28249U105 | CLDNEUR | EIGER BIOPHARMACEUTICALS INC | $4 | 0.00% | 25,100 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.